Margherita Serra

Dr. Margherita Serra

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2023 in The Oncologist
Verified
Journal Article
Open access
GDGerti Dajti
Gerti Dajti
MSMargherita Serra
Margherita Serra
GCGiovanni Cisternino
Giovanni Cisternino
CCClaudio Ceccarelli
Claudio Ceccarelli
APAlice Pellegrini
Alice Pellegrini
SZSimone Zanotti
Simone Zanotti
Purpose: The aim of this study was to evaluate the prognostic role of p53 immunohistochemical (IHC) expression in a large cohort of patients with hormone receptors (HR)-positive/Her2-negative primary invasive breast cancer. Methods: Retrospective review of consecutive cases treated at our Breast Unit between 2003 and 2013. Patients were divided into 3 subgroups based on p53 IHC expression: null (0%), low (0.1%-49%), and high (≥50%) p53 expression. Results: A total of 1387 patients were included in the study with a median follow-up of 86 months. After adjusting for age, size, node status, lymphovascular invasion, progesterone, and Ki67 expression, only null p53 immunophenotype was associated with worse disease-free survival (DFS) (OR 1.74, 95% IC, 1.11-2.71, P = .015) and distant recurrence-free survival (DRFS) (OR 1.73, 95% IC, 1.04-2.90, P = .036). Null p53 impacted significantly DFS and DRFS also in patients with early breast cancer. Conclusions: p53 IHC expression affects survival and, thus can be a valuable tool in the management of patients with HR-positive/Her2-negative breast cancer

1 October 2020 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
MSMargherita Serra
Margherita Serra
ALA. Quattrini Li
A. Quattrini Li
LCL. Cataliotti
L. Cataliotti
ECE. Cianchetti
E. Cianchetti
FCFabio Corsi
Fabio Corsi
VTV.L. Troilo
V.L. Troilo

28 May 2025 in Biochimie
Verified
Journal Article
Open access
GVGiulia Venturi
Giulia Venturi
FZFederico Zacchini
Federico Zacchini
FRFrancesca Ruzzi
Francesca Ruzzi
ACAngelo Gianluca Corradini
Angelo Gianluca Corradini
MSMargherita Serra
Margherita Serra
Lorenzo MontanaroLorenzo Montanaro
Lorenzo Montanaro
Ribosome heterogeneity can contribute to translation regulation in terms of mRNA selection and translation efficiency. This is particularly true for cancer cells in which oncoribosomes are reported to translate mRNAs encoding for proteins involved in cancer progression. Among other factors, a source of ribosome heterogeneity not yet characterized could be represented by 5.8S rRNA and its three forms distinguished based on their 5' sequence. So far, little is known about the role of the presence of these isoforms in mature ribosomes and how they may contribute to human pathology. Here we investigated the relative abundance of the three 5.8S rRNA isoforms in different contexts. Analyzing total and polysomal RNA from cancer cell lines we detected all the three forms recruited in actively translating ribosomes consistently to the basal levels of their expression. Moreover, we showed that changes in the relative abundance of 5.8S rRNA isoforms can be linked to the process of tumorigenesis in a human HER2 transgenic mouse model which develops spontaneous mammary carcinomas. Finally, from the analysis of breast cancer samples, we observed significant correlations between tumor grade, estrogen receptor status and patient prognosis with the relative abundance of 5.8S rRNA isoforms. These results suggest an additional level of complexity involving 5.8S rRNA and ribosome heterogeneity in cancer pathology.

3 November 2025 in Anz Journal of Surgery
Verified
Journal Article
Open access
MBMarco Bernini
Marco Bernini
FSFederico Spolveri
Federico Spolveri
MSMargherita Serra
Margherita Serra
SSSilvia Sordi
Silvia Sordi
CTCinzia Tommasi
Cinzia Tommasi
IMIcro Meattini
Icro Meattini
Background: Implant‐based breast reconstruction (IBBR) is the most common method of breast reconstruction globally. Although the traditional approach places implants in a retropectoral position, pre‐pectoral reconstruction has recently gained popularity due to its improved aesthetic outcomes and lower capsular contracture (CC) rates. However, not all patients are ideal candidates for prepectoral IBBR, making the retropectoral technique still a valuable option. Capsular contracture is a common complication of IBBR, causing discomfort, pain, poor cosmetic results, and often necessitating revision surgery, particularly in retropectoral cases. Selective denervation of the pectoralis major muscle (PMM) in retropectoral IBBR is a novel technique to reduce these complications. Material and Methods: We selected a group of denervated retro‐pec IBBR patients and compared them to non‐denervated patients. In a previous study, we analyzed the subjective opinions on the reconstruction outcomes using the BREAST‐Q postoperative questionnaire. At the same time, we compared retrospectivally the same groups, with a minimum 24‐month follow‐up, from an objective perspective, evaluating CC rates by Baker scale and possible implant malrotation through outpatient clinic visits performed by three independent breast cancer professionals. Results: The overall mean follow‐up was 3.33 (±0.47) years, and the CC rate was significantly lower in Group 1, even adjusting for the propensity score. Conclusions: PMM selective denervation has gained statistical appreciation by women and significantly reduced the CC rate from an objective evaluation in the setting of retro‐pectoral IBBR in our series.

Verified
Journal Article
Open access
PDF file
Diego RaimondoDiego Raimondo
Diego Raimondo
MDMarisol Doglioli
Marisol Doglioli
CFCristian Forastiere
Cristian Forastiere
RVRossella Vicenti
Rossella Vicenti
MSMarco Schirripa
Marco Schirripa
ARAntonio Raffone
Antonio Raffone
Background/Objectives: Breast cancer is the most common malignancy in young women, many of whom face fertility impairment due to gonadotoxic treatments and prolonged endocrine therapy. Ovarian tissue cryopreservation (OTC) has emerged as an alternative fertility preservation (FP) strategy, particularly when controlled ovarian stimulation is not feasible. This study aimed to evaluate the role of OTC in breast cancer patients, with the aim of clarifying its current clinical role and future perspectives within fertility preservation counselling for this population. Methods: A structured SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis was conducted based on the current literature, addressing clinical efficacy, safety, and applicability of OTC in breast cancer patients. Results: Key strengths of OTC include the absence of delay in cancer treatment and the potential to restore both endocrine and reproductive function. However, limitations include the need for surgery, the theoretical risk of reintroducing malignant cells, and variable, less predictable reproductive outcomes compared with gamete-based strategies. Opportunities lie in advances in cryopreservation, transplantation techniques, and integration with in vitro maturation. Major threats include limited data in breast cancer-specific populations, challenges in BRCA mutation carriers, and low utilization rates affecting cost-effectiveness and healthcare sustainability. Conclusions: OTC represents a valuable complementary FP option for selected breast cancer patients, particularly in urgent settings. Despite promising outcomes, its use should remain individualized within multidisciplinary counseling, considering patient-specific oncological and reproductive factors, while further research is needed to clarify long-term safety and efficacy.

28 May 2026 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
MBMarco Bernini
Marco Bernini
SISofia Innocenti
Sofia Innocenti
DTDaniela Turchetti
Daniela Turchetti
SMSara Miccoli
Sara Miccoli
GIGiovanni Innella
Giovanni Innella
MSMargherita Serra
Margherita Serra
This study evaluates the uptake of bilateral risk-reducing mastectomy (BRRM) among unaffected BRCA1/2 mutation carriers in the metropolitan area of Bologna, Italy, between 2012 and 2024. Pathogenic BRCA variants, which confer a markedly increased lifetime risk of breast cancer, are managed through preventive strategies such as BRRM, which can reduce risk by more than 90%.Among 178 women (89 BRCA1 and 89 BRCA2 carriers), 22.5% elected to undergo BRRM, with a significantly higher uptake among BRCA1 carriers (33.7%) compared with BRCA2 carriers (11.2%). Most procedures were performed more than two years after genetic testing, and the most common age at surgery was 41-45 years.Furthermore, the results demonstrate a progressive increase over time in both genetic testing and BRRM uptake, in line with international trends. However, the observed rates remain lower than those reported in Northern Europe. Despite limitations related to cohort size and data completeness, this study provides updated evidence on decision-making regarding BRRM among Italian women at hereditary risk of breast cancer.